Allergic Rhino-Conjunctivitis - Pipeline Insight, 2024

This “Allergic Rhino-Conjunctivitis - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Allergic Rhino-Conjunctivitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Allergic Rhino-Conjunctivitis Understanding

Allergic Rhino-Conjunctivitis: Overview

Allergic rhinoconjunctivitis, which is caused by an allergen, refers to nose and eye problems that occur at least once a week. When only the nose is affected, it is called allergic rhinitis. It is also known as hay fever, “sinus” or “sensitive nose”. When only the eyes are affected, it is called allergic conjunctivitis. Most allergies are due to a combination of genetic and environmental factors. This means that there is often a family member with asthma, allergic rhinoconjunctivitis or eczema. House dust mite allergens are the most common triggers for allergic rhinoconjunctivitis in Singapore. House dust mites are microscopic creatures that reside in homes. Other triggers include pollen, which is most common in temperate climate, and animal dander (a combination of dead skin cells and hair or feathers). Food is rarely a trigger for isolated allergic rhinoconjunctivitis symptoms. The diagnosis of allergic rhinoconjunctivitis in children can be made by taking a history. Four key nasal symptoms exist. Children are often seen for a cough and malaise, and allergic rhinoconjunctivitis is only recognised when symptoms such as nasal congestion, discharge, and itch are specifically asked for. Management in primary care includes education of the patient and parent(s), avoidance of allergens and tobacco smoke, and pharmacotherapy. A stepwise approach is recommended, which depends on the severity of the disorder, the patient's preferences and adherence to treatment, and the presence of comorbidities such as asthma.

Allergic Rhino-Conjunctivitis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Allergic Rhino-Conjunctivitis pipeline landscape is provided which includes the disease overview and Allergic Rhino-Conjunctivitis treatment guidelines. The assessment part of the report embraces, in depth Allergic Rhino-Conjunctivitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Allergic Rhino-Conjunctivitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Allergic Rhino-Conjunctivitis.
• In the coming years, the Allergic Rhino-Conjunctivitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Allergic Rhino-Conjunctivitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Allergic Rhino-Conjunctivitis treatment market. Several potential therapies for Allergic Rhino-Conjunctivitis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Allergic Rhino-Conjunctivitis market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Allergic Rhino-Conjunctivitis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Allergic Rhino-Conjunctivitis Emerging Drugs Chapters

This segment of the Allergic Rhino-Conjunctivitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Allergic Rhino-Conjunctivitis Emerging Drugs

Tacrosolv: Marinomed Biotech AGTacrosolv is an improved formulation of tacrolimus, an immunomodulator that can suppress inflammatory reactions, including allergic symptoms. Tacrolimus was first approved for human use by the U.S. Food and Drug Administration (FDA) in 1994 for use as an immunosuppressant in neurodermitis and graft-versus-host disease. The now off-patent blockbuster drug is poorly soluble in water limiting its usefulness for ophthalmic applications. Formulated with Marinomed’s Marinosolv platform, the solubility of tacrolimus is increased by more than 200-fold compared to water alone enabling the use of tacrolimus as eye drops and enhancing its bioavailability, which allows for significantly lower dosing. Marinomed plans to develop its patent-protected tacrolimus formulation for the treatment of various types of ocular inflammation starting with allergic rhinoconjunctivitis.

ILT-101: ILTOO PharmaILT-101 (Aldesleukin/Proleukin) is a low dose human recombinant interleukin 2 (rhIL2), for the treatment of allergic rhinoconjunctivitic, metastatic renal cell carcinoma and metastatic melanoma. The drug is currently in Phase II stage of clinical trial evaluation to treat patients suffering from allergic rhinoconjunctivitis.

Allergic Rhino-Conjunctivitis: Therapeutic Assessment

This segment of the report provides insights about the different Allergic Rhino-Conjunctivitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Allergic Rhino-Conjunctivitis

There are approx. 5+ key companies which are developing the therapies for Allergic Rhino-Conjunctivitis. The companies which have their Allergic Rhino-Conjunctivitis drug candidates in the most advanced stage, i.e. phase II include, Marinomed Biotech AG.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Allergic Rhino-Conjunctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Allergic Rhino-Conjunctivitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Allergic Rhino-Conjunctivitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Allergic Rhino-Conjunctivitis drugs.

Allergic Rhino-Conjunctivitis Report Insights

• Allergic Rhino-Conjunctivitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Allergic Rhino-Conjunctivitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Allergic Rhino-Conjunctivitis drugs?
• How many Allergic Rhino-Conjunctivitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Allergic Rhino-Conjunctivitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Allergic Rhino-Conjunctivitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Allergic Rhino-Conjunctivitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Marinomed Biotech AG
• ILTOO Pharma
• Emergo Therapeutics
• Immunotek SL
• Roxall Medicina España S.A
• Biomay AG

Key Products

• Tacrosolv
• ILT-101
• Norketotifen
• MM09-MG01
• MM09
• Allergovac Depot
• BM41
• MG01

This product will be delivered within 2 business days.